Acurx Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-8.0M | $-14.1M | $-14.6M | $-12.1M | $-12.7M | $-4.6M |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $1.2M | $2.6M | $3.2M | $2.9M | $5.2M | $695.8K |
| Net Cash from Operating Activities | $-6.8M | $-10.4M | $-9.8M | $-7.5M | $-5.0M | $-3.4M |
| Investing Activities | ||||||
| Capital Expenditures | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $10.6M | $6.6M | $8.2M | $3.7M | $14.8M | $4.0M |
| Net Change in Cash | $3.8M | $-3.8M | $-1.6M | $-3.8M | $9.8M | $692.1K |
| Free Cash Flow | — | — | — | — | — | — |